In COVID-19 clinical update #119, Dr. Griffin reviews tixagevimab for infection prevention, ivermectin for outpatient infection treatment, symptom rebound after PAXLOVID treatment, bamlanivimab minimally impacting immune response to vaccination, in-hospital mortality among infection patients, residual viral antigen in patients following infection, usage of Casirvimab/Imdevimab and Remdesivir in infected patients with depleted B-cells, and rheumatic symptoms following infection.
Click arrow to play
Download TWiV 910 (29 MB .mp3, 48 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Show notes at microbe.tv/twiv
2 thoughts on “TWiV 910: COVID-19 clinical update #119 with Dr. Daniel Griffin”
Comments are closed.